Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc.
Aurobindo Pharma has received the final approval from the US Food and Drug Administration to manufacture and market Atracurium Besylate injection in single and multi-dose vials in the US market.

